Ancillary techniques in the followup of transitional cell carcinoma: a comparison of cytology, histology and deoxyribonucleic acid image analysis cytometry in 91 patients.
Expression of ABH blood group isoantigen as a prognostic factor in transitional cell bladder carcinoma.
Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder.
Growth fractions of transitional cell carcinomas of the bladder defined by the monoclonal antibody Ki-67.
(108.) Prout GR Jr, Lin CW, Benson R JR, Nseyo UO, Daly JJ, Griffin PP et al: Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional cell carcinoma of the bladder.
(112.) Leblanc B, Duclos AJ, Benard F, Cote J, Valiquette L, Paquin JM et al: Long-term follow-up of initial Ta grade 1 transitional cell carcinoma of the bladder.
(113.) Sengupta S and Blute ML: The management of superficial transitional cell carcinoma of the bladder.
Lymphadenectomy in patients with transitional cell carcinoma of urinary bladder; significance of staging and prognosis.